ARTRON COVID-19 RAPID ANTIGEN TEST [pack of 25 tests]
ARTRON COVID-19 RAPID ANTIGEN TEST [pack of 25 tests]
ARTRON COVID-19 RAPID ANTIGEN TEST [pack of 25 tests]
ARTRON COVID-19 RAPID ANTIGEN TEST [pack of 25 tests]
ARTRON COVID-19 RAPID ANTIGEN TEST [pack of 25 tests]

ARTRON COVID-19 RAPID ANTIGEN TEST [pack of 25 tests]

Regular price $375.00
Unit price  per 

These tests are approved for sale in Canada only. For tests approved for sale in the USA, please visit our US store by clicking here.

*For large quantities, please contact us.

PRODUCT INFORMATION

  • Product name: COVID-19 Antigen Test
  • Specimen: Nasopharyngeal/Nasal Swab specimens
  • Sensitivity: 96.7% Specificity 100% 
  • Test Time: 15-30 Minutes
  • Shelf Life: 18 Months
  • Storage Temperature: 2~30 °C

PRODUCT DESCRIPTION

Artron COVID-19 Rapid Antigen Test is a rapid and convenient immunochromatographic assay for the qualitative detection of COVID-19 antigen (viral nucleoprotein) from nasal swab obtained from patients with signs and symptoms of respiratory infection. The device is designed to aid in the rapid diagnosis of COVID-19 Virus infection.

Artron COVID-19 Rapid Antigen Test is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal secretions from individuals suspected of COVID-19 within 6 days of symptom onset and from individuals without symptoms or other epidemiological reasons to suspect COVID-19 infection, when tested twice over two (or three) days with at least 24 hours (and no more than 36 hours) between tests. This test is authorized for use at the Point of Care i.e., in patient care setting.

Results are for the identification of SARS-CoV-2 viral nucleoprotein antigen. Antigens are generally detectable in nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories are required to report all positive results to the appropriate public health authorities.

Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.

The Artron COVID-19 Rapid Antigen Test is intended for use by trained laboratory personnel or health care professionals.

Pursuant to section 5 of the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19, made by the Minister of Health on March 18, 2020, the Artron COVID-19 Rapid Antigen Test is now authorized for sale or importation in Canada. Interim Authorization Number: 321669

Artron COVID-19 Rapid Antigen Test

CLINICAL PERFORMANCE

statistics

CONTENTS

  • Test Cassette
  • Extraction Buffer Bottle (two per box,6ml per bottle, total of 12 ml buffer)
  • Reagent Tube with Cap
  • Sterilized Nasopharyngeal/Nasal Swab
  • Test Instruction 

 

US CUSTOMERS:

These tests are approved for sale in Canada only. For tests approved for sale in the USA, please contact us. 



x

x
x